Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: The role of novel antimold azoles

Oncologist

Volumn 16, Issue 7, 2011, Pages 1049-1060

  Ramos, Elizabeth R ^a   Jiang, Ying ^a   Hachem, Ray ^a   Kassis, Christelle ^a   Kontoyiannis, Dimitrios P ^a   Raad, Issam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Azole; Hematologic malignancy; Invasive aspergillosis; Outcome; Prognostic factor

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN; POSACONAZOLE; STEROID; TACROLIMUS; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; LENGTH OF STAY; LEUKEMIA; LUNG ASPERGILLOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MORTALITY; MYELOMA; NEUTROPENIA; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; AZOLES; CHILD; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960888463     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0290     Document Type: Article

References (27)

1. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999;5(2):55-68.
2. Marr K, Carter R, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplants recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-4366.
3. Garcia-Vidal K, Upton A, Kirby K et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008;47:1041-1050.
4. Marr K, Carter R, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917.
5. Ribaud P, Chastang C, Latge ́ JP et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999;28:322-330.
6. Upton A, Kirby K, Carpenter P et al. Invasive aspergillosis following he-matopoietic transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-540.
7. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006;91:986-989.
8. Ascioglu S, Rex JH, de Pauw B et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in im-munocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
9. Denning D. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-615.
10. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396.
11. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289-1297.
12. Hachem RY, Boktour MR, Hanna HA et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008;112:1282-1287.
13. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus am-photericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
14. Raad II, Hanna HA, Boktour M et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of ampho-tericin B alone or in combination with caspofungin. Leukemia 2008;22: 496-503.
15. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360.
16. Kirkpatrick WR, McAtee RK, Fothergill AW et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44:780-782.
17. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin infect Dis 2007;44:2-12.
18. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356: 335-347.
19. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 56:348-359.
20. Baddley JW, Marr KA, Andes DR et al. Patterns of susceptibility of Asper-gillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009;47:3271-3275.
21. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PloS Med 2008;5:e219.
22. Lamaris GA, Ben-Ami R, Lewis RE et al. Increased virulence of Zygomy-cetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009;199:1399-1406.
23. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-1360.
24. Gallien S, Fournier S, Porcher R et al. Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department. A review of 34 cases. Infection 2008;36:533-538.
25. Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006;42:955-963.
26. Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 39 cases by GIMEMA Infection Program. Haematologica 2001;86:862-870.
27. Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010;95:644-650.